Technical Analysis for RAIN - Rain Therapeutics Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Up | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Volume Surge | Other | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
BB Squeeze + Upper Band Touch | Range Contraction | 0.00% | |
Outside Day | Range Expansion | 0.00% | |
Gapped Up | Strength | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
Jack-in-the-Box Bullish | Bullish Swing Setup | -1.63% | |
Bollinger Band Squeeze | Range Contraction | -1.63% | |
Upper Bollinger Band Walk | Strength | -1.63% | |
BB Squeeze + Upper Band Touch | Range Contraction | -1.63% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/07/2024
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Tumor Prostate Cancer Antineoplastic Drugs Targeted Therapy Tyrosine Kinase Receptors Bemcentinib
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Tumor Prostate Cancer Antineoplastic Drugs Targeted Therapy Tyrosine Kinase Receptors Bemcentinib
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 11.31 |
52 Week Low | 0.82 |
Average Volume | 325,826 |
200-Day Moving Average | 2.14 |
50-Day Moving Average | 1.16 |
20-Day Moving Average | 1.21 |
10-Day Moving Average | 1.22 |
Average True Range | 0.03 |
RSI (14) | 53.92 |
ADX | 34.55 |
+DI | 24.85 |
-DI | 5.61 |
Chandelier Exit (Long, 3 ATRs) | 1.18 |
Chandelier Exit (Short, 3 ATRs) | 1.28 |
Upper Bollinger Bands | 1.23 |
Lower Bollinger Band | 1.18 |
Percent B (%b) | 0.51 |
BandWidth | 4.12 |
MACD Line | 0.02 |
MACD Signal Line | 0.02 |
MACD Histogram | -0.002 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.30 | ||||
Resistance 3 (R3) | 1.31 | 1.29 | 1.29 | ||
Resistance 2 (R2) | 1.29 | 1.27 | 1.29 | 1.28 | |
Resistance 1 (R1) | 1.25 | 1.25 | 1.24 | 1.24 | 1.27 |
Pivot Point | 1.23 | 1.23 | 1.23 | 1.23 | 1.23 |
Support 1 (S1) | 1.19 | 1.21 | 1.18 | 1.18 | 1.15 |
Support 2 (S2) | 1.17 | 1.19 | 1.17 | 1.14 | |
Support 3 (S3) | 1.13 | 1.17 | 1.14 | ||
Support 4 (S4) | 1.12 |